Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

http://www.wikidata.org/entity/Q38466691

about

Lupus Nephritis: A Different Disease in European Patients?Lupus Nephritis in Asia: Clinical Features and Management Current and emerging treatment options in the management of lupus Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Belimumab in systemic lupus erythematosus Use of biologics in SLE: a review of the evidence from a clinical perspective Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research Cellular targeting in autoimmunity Polychromatic flow cytometry in evaluating rheumatic disease patients Profile of atacicept and its potential in the treatment of systemic lupus erythematosus Type I interferon blockade in systemic lupus erythematosus: where do we stand?Understanding the role of B cells in atherosclerosis: potential clinical implications Effect of TACI signaling on humoral immunity and autoimmune diseases B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production Lupus nephritis: the evolving role of novel therapeutics Unmet medical needs in systemic lupus erythematosus Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome Approaches for estimating minimal clinically important differences in systemic lupus erythematosus Rituximab in autoimmune diseases Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities Mechanisms of autoantibody production in systemic lupus erythematosus Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus What is new in the management of rapidly progressive glomerulonephritis?Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America The pathogenesis of systemic lupus erythematosus—an update Treatment of primary Sjögren syndrome.B cells and atherosclerosis.CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Patient-reported outcomes in lupus clinical trials with biologics.The pathogenesis, diagnosis and treatment of lupus nephritis.Prospective data collection of off-label use of rituximab in Australian public hospitals.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Lupus pathobiology based on genomics.Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

P2860

Q26740483-A465A9B2-6EAD-4A1C-9ED3-1F5E9B43990A Q26740487-A813D633-AFF5-49E8-8F47-3815D33A689F Q26741266-39672775-7121-4D44-B98C-64E5840ADA1A Q26746697-FD18FA81-52E3-4813-A7DA-081FDC923BEB Q26774815-0D8A2EF1-BAD0-4AE3-AA38-F5EA26BFBB9F Q26775756-E197C5C9-8377-46C0-9300-B24619B1EA22 Q26778277-668A21C5-5ACE-426E-B979-2F12D6910A2A Q26783652-8D441087-21D9-4749-B825-DD47E9C2EB75 Q26796871-0CE096B2-1A6B-4438-904E-AE03DEDCA7DF Q26799223-3619C255-B45B-487A-975B-8237CDEE4412 Q26824580-08CACE45-4A7B-4943-9CCB-860DC72CDEBE Q26827075-58D502DF-A4A0-4BBC-B20B-9AFCAE01684E Q26849719-C5C0827B-6044-44A5-9613-001D41B09818 Q26865441-51344F88-A205-4BD6-B7C6-F2DC6103C470 Q26991813-FC77C2A2-00FA-401B-B195-FCE3A2FFAA67 Q26995571-01D21EA2-CB88-47FB-9116-FFD99D5A8868 Q26996644-B9DDE70E-F28B-4BC8-9B37-D02C29D523E7 Q26998390-022727EA-E654-40C0-8BC2-5886122656F6 Q27005906-09101439-BEB3-43A6-A3AE-491C078A8D69 Q27021256-2E8DD433-02E8-4B4F-9DAD-8D2731B96B3F Q27021623-B63341F0-9FC0-4FA1-BDEE-613CCE38BE64 Q28076091-A7D60D52-CBEB-4343-9255-FC22163B31E8 Q28080571-AAC86818-786B-4566-9BAC-F7A2CB13E775 Q28082507-E48E8CE4-2EDB-449F-B9AB-1E7F8CC337B5 Q28088753-F63BB9E6-69A3-4E02-B121-6F2C84B294AF Q28259540-3C6206FE-3D9F-461C-BF2A-90BF136AA226 Q28645743-3FBAD8C4-6EB9-43B1-906D-54EC94AA54AE Q29394347-74A895CD-9EB5-418B-B8D5-D8233DEA214D Q30249011-B922A590-56A3-4473-A14E-A0D7388AC0BE Q30252928-FB75C98F-CC15-443D-A2DF-4E3DD66BC0EE Q30388433-4927B8BF-0255-444C-9E84-87FF4CB699D7 Q30391564-0EDD34D5-11AF-46B1-B116-727C5110DEF2 Q30596968-31173204-EB02-492B-865F-E0FF4F849E3C Q30640279-A01442A1-F344-4E28-AE41-0D0CACFA628C Q30832522-161CBDB3-C83E-4122-8BC9-84B9A4875D63 Q33364409-3BE83194-73A1-403F-8A33-FF389B3DA572 Q33407247-CE7501F3-988F-404B-B37B-7625AAA03470 Q33421190-1F111E2F-8198-44D5-91F1-402F645CDE65 Q33431030-8D79C783-9C49-4B37-8FF4-8B8CF93D3639 Q33683956-CE63F826-F5EE-474E-89D5-10AE31C11BDB

P2860

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

http://www.wikidata.org/entity/Q38466691

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy and safety of rituxim ...... sessment with Rituximab study.

@en

type

label

Efficacy and safety of rituxim ...... sessment with Rituximab study.

@en

prefLabel

Efficacy and safety of rituxim ...... sessment with Rituximab study.

@en

P1433

Q38466691-C55A0081-78B2-4AFD-8B36-BDB5410A8E72

P1476

Q38466691-6095EC33-B1FB-44DC-B281-3445C1BC4AA7

P2093

Q38466691-01969248-8E5B-43B9-9F03-54EE1B19C9B6

Q38466691-10AC4A26-ED9C-4AA5-B5F7-36F6CF8D4826

Q38466691-1173507D-0AD2-4092-869D-33774DDE111E

Q38466691-150CC9E7-D984-42A2-85FA-4347488ED70E

Q38466691-1ED41439-3F13-494E-A9A6-700FB68C1878

Q38466691-32B608CE-9973-48B1-B3E8-72E709102FF8

Q38466691-439B8505-84A5-49C5-96FB-B5AED6D974F5

Q38466691-A3432B72-9EDC-4BB3-81FB-E7088499AC50

Q38466691-A45296CB-8128-4E74-81A0-66045929DBB3

Q38466691-B1EC2C04-DF07-4F41-A8EA-0F450F683D40

P2860

Q38466691-051EE79A-1583-4DA7-BE25-9C533AEDF27B

Q38466691-057E1B24-1D93-4E1E-8980-104533EFC340

Q38466691-0C4911B0-9238-4C88-A290-F536667F6F43

Q38466691-168C1F2C-349E-444D-B537-513411C19F26

Q38466691-16CFFB72-3ABD-4363-B5EC-2D85D7D1A130

Q38466691-18D3E72D-9A24-4BFE-8865-F976761C7A66

Q38466691-1B404882-B503-48AA-A823-E25D555336EF

Q38466691-2F053D4B-D20F-401B-903B-2B53EF34ED6B

Q38466691-319CD982-0C12-4D46-A680-5DB578D69712

Q38466691-38BBFDCD-691E-4353-9625-ABEC2798D253

P304

Q38466691-BDF9C8CF-2774-4A24-B9DB-E240AFFAA36B

P31

Q38466691-ABAA2864-CCF3-4813-A1EA-D28669BA3B26

P356

Q38466691-0648A352-CBCC-4C62-97C6-C39F435C17DC

P433

Q38466691-ADE7150C-0E6B-47CC-8234-D2D55754FD27

P478

Q38466691-BF621C47-09E5-4D7A-968D-5B90DB4E15FF

P577

Q38466691-B9D286FA-8EC7-4A83-8425-3A9C8F820ED4

P5875

Q38466691-77D9DA8C-A357-4EB6-81E9-6D4808ECE216

P698

Q38466691-20AB7C3C-23C2-4BFC-82F9-FB612234662C

P921

Q38466691-5C1CE051-691C-4391-AD09-C84BD29EB53D

P356

P1433

Arthritis & Rheumatology

P1476

Efficacy and safety of rituxim ...... sessment with Rituximab study.

@en

P2093

Brad H Rovin

http://www.w3.org/2001/XMLSchema#string

David Zhang

http://www.w3.org/2001/XMLSchema#string

Fernando C Fervenza

http://www.w3.org/2001/XMLSchema#string

Gerald Appel

http://www.w3.org/2001/XMLSchema#string

Jay P Garg

http://www.w3.org/2001/XMLSchema#string

Jorge Sanchez-Guerrero

http://www.w3.org/2001/XMLSchema#string

Kevin Latinis

http://www.w3.org/2001/XMLSchema#string

LUNAR Investigator Group

http://www.w3.org/2001/XMLSchema#string

Paul Brunetta

http://www.w3.org/2001/XMLSchema#string

R John Looney

http://www.w3.org/2001/XMLSchema#string

P2860

The MOS 36-ltem Short-Form Health Survey (SF-36)

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience.

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

P304

1215-1226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.34359

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221734970

http://www.w3.org/2001/XMLSchema#string

P698

22231479

http://www.w3.org/2001/XMLSchema#string

P921